{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-160703","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.841420+00:00","generated_at":"2026-06-01T04:38:53.178045+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IN8bio Phase 1 INB-100 shows 100% durable CR at 1 year in leukemia patients","bullets":["100% of evaluable leukemia patients (n=10) remain in durable CR at 1 year as of May 31, 2024.","First allogeneic cellular therapy to show in vivo gamma-delta T cell expansion/persistence at 365 days.","Favorable safety: no DLTs, CRS, neurotoxicity, or ICANS observed.","Two patients relapse-free >3.5 years; third nearing 3 years post-transplant.","Trial expanded at Dose Level 2; FDA Type B meeting planned this summer for potential registrational path."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-160703","json":"https://secwatch.observer/filing/0001193125-24-160703.json","markdown":"https://secwatch.observer/filing/0001193125-24-160703.md","text":"https://secwatch.observer/filing/0001193125-24-160703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524160703/0001193125-24-160703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524160703/d774911d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:38:53.178045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}